secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001140361-26-000893
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis reports TRYNGOLZA 2025 preliminary U.S. net sales of $105M, ups peak olezarsen guidance to >$2B
--------------------------------------------------------------------------------

- TRYNGOLZA generated $105M in preliminary 2025 U.S. net product sales, outperforming expectations as first FDA-approved FCS treatment.
- Annual peak net sales guidance for olezarsen in sHTG increased to >$2B from >$1B following strong Phase 3 data.
- Submitted sNDA for olezarsen in severe hypertriglyceridemia; potential approval and launch anticipated in 2026.
- Expects 2026 launches of zilganersen for Alexander disease (NDA in Q1) and bepirovirsen for chronic hepatitis B (with GSK).
- Five Phase 3 readouts from partnered programs planned in 2026, including pelacarsen (Novartis) and eplontersen (AstraZeneca).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036126000893/0001140361-26-000893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036126000893/ef20062670_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-000893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer